Clinical Trial Update: Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Bryostatin-1 in Alzheimer's disease reports on safety, efficacy, pharmacokinetics, and pharmacodynamics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bryostatin-1 (bryostatin-1)

Snippet

Sponsor: Blanchette Rockefeller Neurosciences Insitute | Conditions: Alzheimer's Disease | Phase 2 | Status: UNKNOWN